Company Information
Industry 制造业
Company Introduction 公司自设立以来一直专注于POCT(即时检验)领域,主要从事POCT诊断试剂的研发、生产和销售,是我国POCT行业的领先企业之一。 公司的主要产品为POCT快速诊断试剂产品,公司生产的POCT诊断试剂产品基于胶体金/乳胶/荧光颗粒制备与标记技术、免疫层析技术、单克隆抗体技术等研制开发而成,与传统诊断方法相比具有特异性强、灵敏度高、简易快速、成本较低、一般不需要特殊设备并适用于大规模筛查使用等优点,对检验医学领域的发展具有重要意义。 公司是全球POCT诊断试剂品种较为齐全的生产厂商之一,现有产品覆盖了生殖健康检测、药物滥用(毒品)检测、传染病检测、肿瘤标志物检测、心肌标志物检测等五大检测领域,广泛应用于国内外各级医疗机构、司法检测系统、第三方检测机构、疾病预防控制中心、采血站、私人诊所等。在中国国内市场方面,发行人除已获得基础的《医疗器械生产许可证》外,还获得了NMPA注册/备案证书33项,其中一类产品备案证书1项,二类产品注册证书5项,三类产品注册证书27项;国际市场方面,发行人取得欧盟CE证书5项涵盖16个产品(公司3大类传染病产品属于欧盟CE认证listA目录),CE自我声明类产品117项;发行人获得3项美国FDA510(k)证书涵盖21个检测品种。发行人产品已在包括亚洲、北美洲、欧洲、南美洲、非洲等三十多个国家及地区取得相关的注册证书,覆盖了发行人境外销售的全部系列,产品销往全球各地。
Main Business POCT诊断试剂的研发、生产和销售。
Legal Representative 陈音龙
Top Executives
董事长:陈音龙
董事:高红梅,陈宇杰,吴淑江
独立董事:王文明,应国清,王亮
Top 5 Shareholder
Shareholder name Nature Holding Date
杭州拓康投资有限公司流通A股23.34%30/09/2024
于秀萍流通A股16.71%30/09/2024
杭州康宇企业管理咨询合伙企业(有限合伙)流通A股11.25%30/09/2024
陈音龙流通A股3.75%30/09/2024
陈宇杰流通A股3.00%30/09/2024
Company Secretary 费其俊
Solicitors 浙江天册律师事务所
Auditors 中汇会计师事务所(特殊普通合伙)
Tel No 0571-89058091
Fax No 0571-89058091
Website www.biotests.com.cn
Email ir.secretary@biotests.com.cn
Company Address
Register: 浙江省杭州市余杭区中泰街道富泰路17号
Office: 浙江省杭州市余杭区仓前街道途义路27号
Listing Date 08/09/2021
Shares Capital
Shares Capital: 106,666,667
Total A Share: 106,666,667
Listed A Share: 106,666,667
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.000
DPS(RMB)* ¥ 0.800
NBV Per Share(RMB)* ¥ 22.643
Market Capitalization(RMB) 3.605B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.